Communication of the meeting of Transparency Council No. 51/2025 on 1 December 2025 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 51/2025 on 1 December 2025 during which the following resolutions were adopted:

1. At its meeting on 1 December 2025, the Transparency Council adopted position No. 173/2025 on the evaluation of Kayfanda (odeviksibat) for the treatment of pruritus in patients with Alagille syndrome (ICD-10 Q44.7)
2. At its meeting on 1 December 2025, the Transparency Council adopted position No. 174/2025 on the evaluation of Opdivo (nivolumab) under the drug program “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”
3. At its meeting on 1 December 2025, the Transparency Council adopted position No. 175/2025 on the evaluation of Yervoy (ipilimumab) as part of the drug program “Treatment of patients with colorectal cancer (ICD-10: C18-C20)”
4. At its meeting on 1 December 2025, the Transparency Council adopted opinion No. 210/2025 on recommended medical technologies, measures implemented as part of health policy programs, and the conditions for implementing these programs, concerning the prevention and early detection of head and neck cancers

Transparency Council meeting protocol >>